Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 25 articles:
HTML format
Text format

Single Articles

    April 2019
  1. NEWTON C, Murali K, Ahmad A, Hockings H, et al
    A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2019;113:19-27.
    PubMed     Text format     Abstract available

    February 2019
  2. DELLE MARCHETTE M, Ceppi L, Andreano A, Bonazzi CM, et al
    Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery.
    Eur J Cancer. 2019;111:61-68.
    PubMed     Text format     Abstract available

  3. ANDERSSON TM, Engholm G, Lund AQ, Lourenco S, et al
    Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer.
    Eur J Cancer. 2019;110:42-48.
    PubMed     Text format     Abstract available

  4. FRIJSTEIN MM, Lok CAR, Short D, Singh K, et al
    The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.
    Eur J Cancer. 2019;109:162-171.
    PubMed     Text format     Abstract available

    January 2019
  5. JORGENSEN SL, Mogensen O, Wu CS, Korsholm M, et al
    Survival after a nationwide introduction of robotic surgery in women with early-stage endometrial cancer: a population-based prospective cohort study.
    Eur J Cancer. 2019;109:1-11.
    PubMed     Text format     Abstract available

    November 2018
  6. MENZER C, Beedgen B, Rom J, Duffert CM, et al
    Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.
    Eur J Cancer. 2018;104:239-242.
    PubMed     Text format    

    September 2018
  7. CAMPONE M, Im SA, Iwata H, Clemons M, et al
    Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
    Eur J Cancer. 2018;103:147-154.
    PubMed     Text format     Abstract available

    July 2018
  8. BOUVARD B, Chatelais J, Soulie P, Hoppe E, et al
    Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
    Eur J Cancer. 2018;101:87-94.
    PubMed     Text format     Abstract available

  9. BRETTHAUER M, Goderstad JM, Loberg M, Emilsson L, et al
    Uterine morcellation and survival in uterine sarcomas.
    Eur J Cancer. 2018;101:62-68.
    PubMed     Text format     Abstract available

  10. HESCOT S, Haissaguerre M, Pautier P, Kuhn E, et al
    Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect.
    Eur J Cancer. 2018;97:57-58.
    PubMed     Text format    

    June 2018
  11. MEYS EMJ, Jeelof LS, Ramaekers BLT, Dirksen CD, et al
    Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer.
    Eur J Cancer. 2018;100:55-64.
    PubMed     Text format     Abstract available

    May 2018
  12. FRAZIER AL, Stoneham S, Rodriguez-Galindo C, Dang H, et al
    Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium.
    Eur J Cancer. 2018;98:30-37.
    PubMed     Text format     Abstract available

  13. MANDALA M, Merelli B, Indriolo A, Tondini C, et al
    Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
    Eur J Cancer. 2018;95:130-132.
    PubMed     Text format    

    April 2018
  14. NABIEVA N, Fehm T, Haberle L, de Waal J, et al
    Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Eur J Cancer. 2018;96:82-90.
    PubMed     Text format     Abstract available

  15. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
    Eur J Cancer. 2018;95:59-67.
    PubMed     Text format     Abstract available

  16. PLOQUIN A, Pistilli B, Tresch E, Frenel JS, et al
    5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
    Eur J Cancer. 2018;95:30-37.
    PubMed     Text format     Abstract available

  17. MOKE DJ, Thomas SM, Hiemenz MC, Nael A, et al
    Three synchronous malignancies in a patient with DICER1 syndrome.
    Eur J Cancer. 2018;93:140-143.
    PubMed     Text format    

    January 2018
  18. PEDERSEN K, Burger EA, Nygard M, Kristiansen IS, et al
    Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Eur J Cancer. 2018;91:68-75.
    PubMed     Text format     Abstract available

  19. DUHIL DE BENAZE G, Pacquement H, Faure-Conter C, Patte C, et al
    Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.
    Eur J Cancer. 2018;91:30-37.
    PubMed     Text format     Abstract available

    November 2017
  20. TIMMERMANS M, Sonke GS, Van de Vijver KK, van der Aa MA, et al
    No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.
    Eur J Cancer. 2017;88:31-37.
    PubMed     Text format     Abstract available

  21. TEMKIN SM, Miller EA, Samimi G, Berg CD, et al
    Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
    Eur J Cancer. 2017;87:182-188.
    PubMed     Text format     Abstract available

  22. ANDERSON RA, Mansi J, Coleman RE, Adamson DJA, et al
    The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Eur J Cancer. 2017;87:58-64.
    PubMed     Text format     Abstract available

    October 2017
  23. VERSLUIS MAC, Marchal S, Plat A, de Bock GH, et al
    The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
    Eur J Cancer. 2017;86:285-295.
    PubMed     Text format     Abstract available

  24. VERMEULEN RFM, Beurden MV, Kieffer JM, Bleiker EMA, et al
    Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Eur J Cancer. 2017;84:159-167.
    PubMed     Text format     Abstract available

    September 2017
  25. VANDERSTICHELE A, Busschaert P, Olbrecht S, Lambrechts D, et al
    Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2017;86:5-14.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.